Xamamina 6 Capsule 50mg,Xamamina 6 Capsule 50mg,BRACCO SPA DIV.

“ACTIVE substances: 50 mg soft capsules: dimenidrinato 50 mg. Children 25 mg soft capsules: dimenidrinato 25 mg. 25 mg chewing gum medicated: dimenidrinato 25 mg.
Excipients: 50 mg soft capsules and Children 25 mg soft capsules: macrogol 400. Metal body. ucr: gelatin; sorbitol liquid is partially dehydrated; sodium parad drossibenzoato ethyl (E215); sodioparaidrossibenzoato to propylparaben (e 217). 25 mg chewing gum self-medication. Core: acid copolymer or methacrylic type, sorbitol, mint flavor, magnesium stearate, rubber base, levomenthol, aspartame, talc, colloidal silicon dioxide, tricalcio fos fate anhydrous; Coating: hypromellose, macrogol 6000, titanium diossid or yellow quinoline (E104), blue patent V (E131).
INDICATIONS: Nausea at sea, plane, car and train.
CONTRAINDICATIONS/EFF.SECONDARY: Hypersensitivity to the active substance, other antihistamines or to any of the excipients. Contraindicated in children under the age of 2 years. Contraindicated for use during pregnancy and lactation.
DOSAGE: 50 mg soft capsules: in adults, 1 soft capsule half an hour before v magg; if necessary, repeat dose after 3-4 hours, up to 4 softgels over 24 hours. Children 25 mg soft capsules. In ba mb aged between 2-6 years: 1 soft capsule half an hour before travel up to 3 times within 24 hours. In children aged between 7 -12 years, 1-2 soft capsules half an hour before travel, up to mass imo 2-3 times every 24 hours. 25 mg medicated chewing gum: in adults 1 chewing gum medicated first symptoms of nausea; takes about 4 hours to complete. If the dose needs to be repeated after 3-4 hours, up to 4 chewing gums are treated within 24 hours. In children aged 4 to 12 years, 1 chewing gum average half an hour before travel or for the first symptoms of nausea and vomiting and, if the dose needs to be repeated after 6-8 hours, a maximum of 2 chewing gum medicaid within 24 hours. Do not exceed the recommended dose of liaohe.
STORAGE: soft capsules: store at a temperature not exceeding 25 degrees C.
WARNINGS: The product should be prescribed with caution in patients with angle-closure glaucoma, prostatic hypertrophy, and urinary retention. a., slowed intestinal transit, bronchial asthma, epilepsy, porphyria. The product may mask symptoms of ototoxicity and pertanto should be prescribed with caution in patients on therapy with ototoxic drugs. The capsules are soft and chewable by medicaid and contain sorbitol: Patients with rare hereditary problems of fructose intolerance should not take this medicine. L and softgels contain parabens, which may cause aller reactions (also delay). Chewing gum for self-medication contains asp article, a source of phenylalanine. This may be harmful if he suffers from phenylketonuria.
INTERACTIONS: The product may increase the effects of other Central Nervous System depressants such as alcohol, barbiturates, other hypnotics, drugs or tranquilizers. In case of reception at the same time, I know such rooms, you should pay attention in order to avoid the phenomena of add Hittite sedation. The product may potentiate the effects of other anticholinergic drugs, including antidepressants. When administered in combination with aminoglycoside antibiotics or other drugs or totossici, and dimenidrinato may mask the early symptoms of ototoss icita’, which can only be detected when the damage is already irreversible.
SIDE EFFECTS: Metabolic and nutritional disorders. Common: anorexia. Deaf psychiatric. Less common: insomnia, agitation. Nervous system disorders. More and more often: sedation, drowsiness; frequent: ce of the fire; less frequent: dizziness, tremor, convulsions. Dell’s turmoil in life. Common: accommodation disturbances. Cardiac disorders. I am not there answers: tachycardia. Vascular disorders. Less frequent: ipoten siya. Gastrointestinal disorders. Common: dry mouth, nausea. Disorders of the skin and subcutaneous tissue. frequency: f tosensibilita’, skin reaction based on allergies. Diseases of the kidneys and urinary tract. Common: urinary disorders. Disorders general conditions iz of the administration site. Less common: asthenia. Reporting and any suspected adverse reactions through the national reporting system.
PREGNANCY AND BREAST-FEEDING: In reproductive studies in rats and rabbits, doses higher than 20-25 times those typically used in human therapy have not been shown to cause teratogenic effects or reduce fertility. Not all available data on the use of the product in women are not pregnant. Thus, although the product is unlikely to have a teratogenic effect, the use of dimenidrinato during pregnancy is contraindicated. Small amounts of dimenidrinato pass into breast milk. Data, possible side effects of the product in infants, use of dimenidri born during breastfeeding”